Ginkgo Bioworks
DNA
320 hedge funds and large institutions have $1.68B invested in Ginkgo Bioworks in 2022 Q4 according to their latest regulatory filings, with 88 funds opening new positions, 120 increasing their positions, 56 reducing their positions, and 43 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 120 | Existing positions reduced: 56
105% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 43
67% more call options, than puts
Call options by funds: $11.4M | Put options by funds: $6.83M
15% more funds holding
Funds holding: 278 → 320 (+42)
0.02% more ownership
Funds ownership: 1.84% → 1.86% (+0.02%)
39% less capital invested
Capital invested by funds: $2.74B → $1.68B (-$1.06B)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$92.2M |
| 2 |
SIAU
SB Investment Advisers (UK)
London,
United Kingdom
|
+$56.2M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$40.4M |
| 4 |
BlackRock
New York
|
+$36.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$89.1M |
| 2 |
NSGL
No Street GP LP
San Francisco,
California
|
-$9.36M |
| 3 |
Morgan Stanley
New York
|
-$7.27M |
| 4 |
TCM
Trybe Capital Management
Greenwich,
Connecticut
|
-$3.29M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.91M |
DNA Hedge Fund Activity: Q4 2022 in Review
320 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q4 2022, worth a combined $1.68B — down 39% from $2.74B a quarter earlier.
Buyers outnumbered sellers: 88 funds opened new DNA positions and 43 closed out — a net gain of 45 holders — while 120 added to existing stakes and 56 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $92.2M. The largest seller was Viking Global Investors, cutting an estimated $89.1M.
- 320 institutional investors held Ginkgo Bioworks (DNA) as of Q4 2022, up from 278 in Q3 2022.
- Funds reported $1.68B of Ginkgo Bioworks stock for Q4 2022, down 39% quarter-over-quarter.
- 88 funds opened new Ginkgo Bioworks positions in Q4 2022 and 43 closed out, a net change of +45 holders.
- The largest Ginkgo Bioworks buyer in Q4 2022 was Baillie Gifford & Co, an estimated $92.2M added.
- The largest Ginkgo Bioworks seller in Q4 2022 was Viking Global Investors, an estimated $89.1M sold.
Based on aggregated 13F filings for Q4 2022.